Form 8-K - Current report:
SEC Accession No. 0001193125-25-120763
Filing Date
2025-05-15
Accepted
2025-05-15 16:00:32
Documents
19
Period of Report
2025-05-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d63848d8k.htm   iXBRL 8-K 71254
2 EX-3.1 d63848dex31.htm EX-3.1 77013
3 EX-10.1 d63848dex101.htm EX-10.1 25493
4 EX-10.2 d63848dex102.htm EX-10.2 22925
5 EX-10.3 d63848dex103.htm EX-10.3 25035
6 EX-99.1 d63848dex991.htm EX-99.1 51461
10 GRAPHIC g63848g0515104529170.jpg GRAPHIC 2512
  Complete submission text file 0001193125-25-120763.txt   473321

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA jagx-20250513.xsd EX-101.SCH 2878
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE jagx-20250513_lab.xml EX-101.LAB 18740
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE jagx-20250513_pre.xml EX-101.PRE 11726
21 EXTRACTED XBRL INSTANCE DOCUMENT d63848d8k_htm.xml XML 3843
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36714 | Film No.: 25952324
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)